12.81 (-%)
As of Dec 04, 2024
Source:
Stoke Therapeutics, Inc is dedicated to addressing the underlying causes of severe diseases by upregulating protein expression with RNA-based medicines. Using our proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, we are developing antisense oligonucleotides (“ASOs”) to selectively restore protein levels. Our first compound, STK-001, is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy.
Country | United States |
Headquarters | bedford, massachusetts |
Phone Number | 781-430-8200 |
Industry | manufacturing |
CEO | Edward M. Kaye, M.D. |
Website | www.stoketherapeutics.com |